Table 1:
Characteristics of monoclonal antibody biologics and indications for use
| Biologic type | Drug name | Structure | Indication for use* |
|---|---|---|---|
| Anti-TNFα | Infliximab | Chimeric anti-TNFα IgG1 | Rheumatoid arthritis, ankylosing spondylitis, Crohn disease, ulcerative colitis, plaque psoriasis |
| Adalimumab | Recombinant humanized anti-TNFα IgG1 | Rheumatoid arthritis, polyarticular JIA, psoriatic arthritis, ankylosing spondylitis, Crohn disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis | |
| Golimumab | Humanized anti-TNFα IgG1 | Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, nonradiographic axial spondyloarthritis, ulcerative colitis | |
| Certolizumab pegol | Recombinant, humanized antibody to the antigen-binding fragment to anti-TNFα | Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis | |
| Etanercept | Human recombinant TNFα receptor/IgG1-Fc fusion protein | Ankylosing spondylitis, rheumatoid arthritis, polyarticular JIA, psoriatic arthritis, plaque psoriasis | |
| Anticytokine | Ustekinumab | Anti-IL-12 and IL-23 humanized IgG1 | Plaque psoriasis, psoriatic arthritis, Crohn disease, ulcerative colitis |
| Tocilizumab | Anti-IL-6 receptor humanized IgG1 | Rheumatoid arthritis, polyarticular and systemic JIA, giant cell arteritis | |
| Canakinumab | Anti-IL-1β human IgG1 | CAPS, TRAPS, HIDS, MKD, FMF, systemic JIA | |
| Anti-integrin | Vedolizumab | Humanized anti-α4β7 integrin IgG1 | Ulcerative colitis, Crohn disease |
| Natalizumab | Anti-integrin α4 subunit humanized IgG4 | Multiple sclerosis | |
| Anti-B cell | Rituximab | Anti-CD20 IgG1 | Rheumatoid arthritis, non-Hodgkin lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis |
| Belimumab | Anti-B-cell activating factor human IgG1 | Systemic lupus erythematosus |
Note: CAPS = cryopyrin-associated periodic syndromes, FMF = familial Mediterranean fever, HIDS = hyperimmunoglobulin D syndrome, Ig = immunoglobulin, IL = interleukin, JIA = juvenile idiopathic arthritis, MKD = mevalonate kinase deficiency, TNF = tumour necrosis factor, TRAPS = tumour necrosis factor receptor associated periodic syndrome.
*
Off-label use not listed.